scholarly journals Personality traits of Lebanese patients with schizophrenia: Comparison by gender and severity of psychosis

2019 ◽  
Author(s):  
Joseph E Dib ◽  
Chadia Haddad ◽  
Ilige Nehme ◽  
Jocelyne Azar ◽  
Ghina Al Seddik ◽  
...  
Keyword(s):  
Personality Traits ◽  
Personality Trait ◽  
Healthy Subjects ◽  
Psychotic Symptoms ◽  
Healthy Individuals ◽  
Healthy Group ◽  
Dsm 5 ◽  
Syndrome Scale ◽  
Schizophrenic Patients ◽  
Negative Syndrome

Abstract Objectives Schizophrenia is known as a mental disease affecting how an individual will reply to a certain scenario in a way that differs from a person to another. A specific personality trait can influence the expressions of psychotic symptoms and affect illness courses. Our aim during this study was to spot nonadaptive personality traits in Lebanese Schizophrenic patients and compare them to healthy subjects.Methods We took a pair of teams one schizophrenic individuals (n=250) and the other healthy individuals (n=250). For the data assortment the tools used were: personality inventory for the DSM-5 (PID-5-BF) brief type, to assess the maladaptive personality traits; Positive and Negative Syndrome Scale (PANSS), to determine the severity of psychotic symptoms in schizophrenic individuals.Results The results were a considerably higher mean in detachment, antagonism and psychoticism personality traits in schizophrenic subjects compared to healthy group. When comparing personality based on the gender a considerably higher mean of negative affect and psychoticism was found in women compared to men, as for the antagonism and detachment it had been considerably higher in men.Conclusion In conclusion, we can say that schizophrenic subjects have a particular personality trait totally different from the overall healthy subjects.

Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET study

2010 ◽  
Vol 25 (11) ◽  
pp. 1462-1468 ◽  
Author(s):  
Emma Barkus ◽  
Paul D Morrison ◽  
D Vuletic ◽  
John C Dickson ◽  
Peter J Ell ◽  
...  
Keyword(s):  
Single Photon ◽  
Photon Emission ◽  
Occipital Cortex ◽  
Psychotic Symptoms ◽  
Double Blind ◽  
Syndrome Scale ◽  
Schizophrenic Patients ◽  
Negative Syndrome ◽  
Psychotomimetic Effects ◽  
Da Release

Intravenous (IV) Δ9-tetrahydrocannabinol (THC) induces transient psychotic symptoms in healthy subjects and in schizophrenic patients, but the psychotomimetic mechanism is unknown. One possibility is that THC stimulates dopamine (DA) release in the striatum. In this study we tested whether IV THC led to an increase in striatal DA release compared to placebo. We also investigated whether DA release and positive psychotic symptoms were related. Eleven healthy male volunteers completed two 123I-iodobenzamide ([123I]IBZM) single photon emission tomography (SPET) sessions and received IV THC (2.5 mg) or placebo in a randomized counterbalanced order, under double-blind conditions. Analysable data were obtained from nine participants. The Positive and Negative Syndrome Scale (PANSS) was used to rate psychotomimetic effects. Striatal binding index values were calculated using the occipital cortex as a reference region. Both the PANSS positive and general symptoms increased significantly at 30 min following IV THC. There were no significant differences in binding index in the caudate or putamen under THC compared to placebo conditions. Positive psychotic symptoms and DA release were unrelated. THC did not lead to a significant increase in DA release even though the dose was sufficient for participants to have psychotic symptoms. These findings do not support a central role for striatal DA in THC-elicited psychosis.

Sinistrality in subtypes of schizophrenia

2002 ◽  
Vol 17 (5) ◽  
pp. 272-277 ◽  
Author(s):  
Sonia Dollfus ◽  
Jacqueline A. Buijsrogge ◽  
Karim Benali ◽  
Pascal Delamillieure ◽  
Perrine Brazo
Keyword(s):  
Negative Correlation ◽  
Language Disorders ◽  
Normal Process ◽  
Deficit Syndrome ◽  
Syndrome Scale ◽  
Schizophrenic Patients ◽  
Dsm Iv ◽  
Negative Syndrome ◽  
Hemisphere Specialization

SummarySinistrality, characterized by an excess of non-right-handedness, has been reported in schizophrenic patients, but the findings are controversial.Aim.As sinistrality could be linked to a failure of hemisphere specialization in schizophrenia that would translate into language disorders, sinistrality was found out in disorganized and positive schizophrenic patients characterized by language disorders.Methods.Seventy-three schizophrenic patients (DSM IV) and 81 controls were evaluated with the Edinburgh Handedness Inventory (EHI). Patients were evaluated and classified into five subtypes (deficit, positive, disorganized, mixed and residual) with the Positive and Negative Syndrome Scale and the Schedule for the Deficit Syndrome.Results.Disorganized patients had a significantly more severe sinistrality in comparison to the deficit, residual and mixed subtypes and controls. A negative correlation was found between the disorganization and the EHI scores (r = – 0.34; P < 0.01). A significantly more severe sinistrality was also observed in the positive subtype in comparison to controls, but there was no correlation between hallucinatory and EHI scores (r = 0.06).Conclusion.The findings provided further evidence that the defects in the normal process of lateralization observed in schizophrenia affects primarily disorganized patients.

Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study

2016 ◽  
Vol 33 (S1) ◽  
pp. s226-s226
Author(s):  
Y.S. Woo ◽  
J.E. Park ◽  
D.H. Kim ◽  
I.K. Sohn ◽  
T.Y. Hwang ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Atypical Antipsychotics ◽  
Therapeutic Strategy ◽  
Psychiatric Symptoms ◽  
Open Label ◽  
Prospective Multicenter Study ◽  
Syndrome Scale ◽  
Schizophrenic Patients ◽  
Competing Interest ◽  
Negative Syndrome

IntroductionEvidences for antipsychotics augmentation for schizophrenic patients with suboptimal efficacy have been lacking although it has been widespread therapeutic strategy in clinical practice.ObjectivesThe purpose of this study was to investigate the efficacy and tolerability of blonanserin augmentation with an atypical antipsychotics (AAPs) in schizophrenic patients.MethodsA total of 100 patients with schizophrenia partially or completely unresponsive to treatment with an AAP recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to existing AAPs which were maintained during the study period. Efficacy was primarily evaluated using Positive and Negative Syndrome Scale (PANSS) at baseline, week 2, 4, 8, and 12. Predictors for PANSS response (≥ 20% reduction) was investigated.ResultsThe PANSS total score was significantly decreased at 12 weeks after blonanserin augmentation (–21.0 ± 18.1, F = 105.849, P < 0.001). Response rate on PANSS at week 12 was 51.0%. Premature discontinuation was occurred in 17 patients (17.0%) and 4 patients among them discontinued the study due to adverse events. Nine patients experienced significant weight gain during the study. Response to blonanserin augmentation was associated with severe (PANSS > 85) baseline symptom (OR = 10.298, P = 0.007) and higher dose (> 600 mg/day of chlorpromazine equivalent dose) of existing AAPs (OR = 4.594, P = 0.014).ConclusionsBlonanserin augmentation improved psychiatric symptoms of schizophrenic patients in cases of partial or non-responsive to an AAP treatment with favorable tolerability. Patients with severe symptom despite treatment with higher dose of AAP were benefited from this augmentation. These results suggested that blonanserin augmentation could be an effective strategy for specific patients with schizophrenia.Disclosure of interestThe authors have not supplied their declaration of competing interest.

A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients

2005 ◽  
Vol 72 (2-3) ◽  
pp. 123-129 ◽  
Author(s):  
A. Fresán ◽  
C. De la Fuente-Sandoval ◽  
C. Loyzaga ◽  
M. Garcı́a-Anaya ◽  
N. Meyenberg ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Concurrent Validity ◽  
Syndrome Scale ◽  
Schizophrenic Patients ◽  
Negative Syndrome

Psychopathology and personality traits in psychotic patients and their first-degree relatives

2009 ◽  
Vol 24 (7) ◽  
pp. 476-482 ◽  
Author(s):  
M.J. Cortés ◽  
J. Valero ◽  
J.A. Gutiérrez-Zotes ◽  
A. Hernández ◽  
L. Moreno ◽  
...  
Keyword(s):  
Personality Traits ◽  
Factor Model ◽  
Five Factor Model ◽  
Point Of View ◽  
Psychotic Symptoms ◽  
Control Group ◽  
Personality Dimensions ◽  
First Degree Relatives ◽  
Schizophrenic Patients ◽  
Self Transcendence

AbstractPersonality dimensions have been associated with symptoms dimensions in schizophrenic patients (SP). In this paper we study the relationships between symptoms of functional psychoses and personality dimensions in SP and their first-degree relatives (SR), in other psychotic patients (PP) and their first-degree relatives (PR), and in healthy controls in order to evaluate the possible clinical dimensionality of these disorders. Twenty-nine SP, 29 SR, 18 PP, 18 PR and 188 controls were assessed using the temperament and character inventory (TCI-R). Current symptoms were evaluated with positive and negative syndrome scale (PANSS) using the five-factor model described previously (positive [PF], negative [NF], disorganized [DF], excitement [EF] and anxiety/depression [ADF]). Our TCI-R results showed that patients had different personality dimensions from the control group, but in relatives, these scores were not different from controls. With regard to symptomatology, we highlight the relations observed between harm avoidance (HA) and PANSS NF, and between self-transcendence (ST) and PANSS PF. From a personality traits-genetic factors point of view, schizophrenia and other psychosis may be initially differentiated by temperamental traits such as HA. The so-called characterial traits like ST would be associated with the appearance of psychotic symptoms.

Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia

2007 ◽  
Vol 37 (10) ◽  
pp. 1427-1436 ◽  
Author(s):  
NIELS BERGEMANN ◽  
PETER PARZER ◽  
BENNO RUNNEBAUM ◽  
FRANZ RESCH ◽  
CHRISTOPH MUNDT
Keyword(s):  
Menstrual Cycle ◽  
Rating Scale ◽  
Premenopausal Women ◽  
Psychotic Symptoms ◽  
Cycle Phase ◽  
Syndrome Scale ◽  
Regular Menses ◽  
Psychiatric Rating ◽  
Psychiatric Rating Scale ◽  
Negative Syndrome

ABSTRACTBackgroundEstrogen has been hypothesized to have a protective and antipsychotic-like effect in women at risk for schizophrenia. The aim of the present study was to evaluate the association between menstrual cycle and/or estrogen levels and psychotic symptoms in a sample of women with schizophrenia.MethodOne hundred and twenty-five premenopausal women with schizophrenia and regular menses were examined. The levels of 17β-estradiol and other hormones of the gonadal axis were assessed in the follicular, peri-ovulatory, and luteal phases of the menstrual cycle. The effects of the menstrual cycle phase and/or the estradiol level on the Positive and Negative Syndrome Scale (PANSS) and the Brief Psychiatric Rating Scale (BPRS) scores were calculated by means of regression analyses.ResultsSignificant improvement in psychotic, but not depressive, symptoms was observed during the luteal phase, compared with other days of the menstrual cycle.ConclusionsThe present findings indicate that estradiol may have specific antipsychotic-like effects on the symptoms of schizophrenia. Thus further investigation into the therapeutic effect of estrogen may be worthwhile.

Influence ofNRGNrs12807809 polymorphism on symptom severity in individuals with schizophrenia in the Han population but not the Zhuang population of south China

2015 ◽  
Vol 27 (4) ◽  
pp. 221-227 ◽  
Author(s):  
Li Su ◽  
Jianxiong Long ◽  
Runde Pan ◽  
Xinfeng Xie ◽  
Xixiang Mao ◽  
...  
Keyword(s):  
South China ◽  
Clinical Symptoms ◽  
Subscale Score ◽  
Assay Method ◽  
Psychotic Symptoms ◽  
Han Population ◽  
Syndrome Scale ◽  
General Activation ◽  
Negative Syndrome ◽  
Pooled Samples

BackgroundNRGNis one of the most promising candidate genes for schizophrenia based on function and position. Therefore, this study aimed to examine the genetic association of this polymorphism with schizophrenia in the Zhuang and Han populations of south China.Subjects and methodsA total of 282 patients (188 Han and 94 Zhuang) and 282 healthy subjects (188 Han and 94 Zhuang) were recruited. Of these, 246 schizophrenia patients underwent an assessment of psychotic symptoms using the Positive and Negative Syndrome Scale (PANSS). A TaqMan genotyping assay method was used to determine the genotypes.ResultsWe did not find a significant association of rs12807809 polymorphism with schizophrenia in the total pooled samples, or in the separate ethnic groups. However, in Han schizophrenia patients, quantitative data analyses showed that the CC genotype of the rs12807809 polymorphism was associated with PANSS aggression subscale score and activation subscale score. Furthermore, carriers of the C allele of rs12807809 polymorphism among Han schizophrenia patients had higher scores of general, activation, depression, aggression, and global symptoms than the T allele carriers.ConclusionIn conclusion rs12807809 polymorphism may not contribute to the risk of schizophrenia but influence the clinical symptoms of schizophrenia in the Han population.

Psychopathological Dimensions and Lack of Insight in Schizophrenia

1998 ◽  
Vol 83 (3) ◽  
pp. 895-898 ◽  
Author(s):  
Manuel J. Cuesta ◽  
Victor Peralta ◽  
Amalia Zarzuela
Keyword(s):  
Multidimensional Approach ◽  
Syndrome Scale ◽  
Schizophrenic Patients ◽  
Negative Syndrome

The present study investigated the relationships of psychopathological dimensions of schizophrenia with Insight in a sample of 100 acute schizophrenic patients. Lack of insight was significantly correlated with disorganized, excited and negative schizophrenic dimensions but not with other Positive and Negative Syndrome Scale dimensions. In addition, when insight was assessed through a multidimensional approach, a variety of relationships with the schizophrenic dimensions were found.

Tolerability and treatment response in patients with recently diagnosed vs. chronic schizophrenia treated with paliperidone ER

2011 ◽  
Vol 26 (S2) ◽  
pp. 1502-1502
Author(s):  
A. Schreiner ◽  
D. Hoeben ◽  
C. Tessier ◽  
M. Lahaye ◽  
J. Turczynski ◽  
...  
Keyword(s):  
Treatment Response ◽  
Chronic Schizophrenia ◽  
Psychotic Symptoms ◽  
Chronic Patients ◽  
Open Label ◽  
Patient Functioning ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Mean Time ◽  
Time Since Diagnosis

ObjectiveTo explore tolerability and treatment response in adult patients with recently diagnosed (<5 years) and chronic (>5 years) schizophrenia treated with flexible doses of paliperidone ER.MethodsInternational prospective open-label 6-month study. Endpoints were the Positive and Negative Syndrome Scale (PANSS), patient functioning and treatment-emergent adverse events (TEAEs).ResultsOf 713 recently diagnosed patients, most were male (60.9%), mean age was 33.6 ± 11.2 years and mean time since diagnosis was 2.3 ± 1.7 years. Chronic patients (n = 1003) were predominantly male (59.2%) with a mean age of 43.8 ± 11.4 and mean time since diagnosis of 15.6 ± 9.2 years. 70.4% and 71.7% of patients completed the study, respectively. Mean mode doses of paliperidone ER were similar between recently diagnosed and chronic patients (7.0 ± 2.9 mg/day and 7.2 ± 2.9 mg/day). 63.1% of recently diagnosed and 60.8% of chronic patients switching due to lack of efficacy with their previous antipsychotic had a >20% improvement in PANSS total score at endpoint, and improvement with other switching reasons was consistently numerically higher in recently diagnosed patients. The rate of patients with mild or no functional impairment increased from 17.7% to 39.8% in recently diagnosed and from 14.4% to 32.9% in chronic patients. TEAEs reported in >5% were insomnia (10.7% and 8.1%), anxiety (8.6% and 6.0%) and somnolence (5.8% and 3.4%), respectively.ConclusionThese data suggest that both recently diagnosed and chronic patients previously unsuccessfully treated with other oral antipsychotics may benefit from paliperidone ER, with a tendency for recently diagnosed patients showing some higher treatment response in psychotic symptoms and patient functioning.

Sign in / Sign up

Export Citation Format

Share Document